Drug selection
Although three different CGRP MoAbs are approved in Europe since 2018: erenumab, galcanezumab and fremanezumab, erenumab and galcanezumab were the two first funded CGRP MoAbs for migraine prevention in our hospital back in late 2019, therefore these were the selected ones for the present study. Erenumab 140 mg was administered every 4 weeks and galcanezumab 120 mg once monthly. For galcanezumab an initial dose of 240 mg during the first month was required. CGRP MoAbs were administered via subcutaneous injection.